CoChat

VALsartan In Acute Myocardial Infarction (VALIANT) Trial: Baseline Characteristics in Context

Velazquez, Eric J., Pfeffer, Marc A., McMurray, John V., Maggioni, Aldo P., Rouleau, Jean-Lucien, Van de Werf, Frans, Kober, Lars, White, Harvey D., Swedberg, Karl, Leimberger, Jeffrey D., Gallo, Paul, Sellers, Mary Ann, Edwards, Susan, Henis, Marc, Califf, Robert M., for the VALIANT Investigators · 2003 · European Journal of Heart Failure
Cited by 95

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Background: The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial compared outcomes with: (1) angiotensin-converting enzyme inhibition (ACEI) with the reference agent captopril; (2) angiotensin-receptor blockade (ARB) with valsartan; or (3) both in patients with heart failure (HF) and/or left ventricular systolic dysfunction (LVSD) after myocardial infarction (MI). Aims: A goal of this active-control trial was to simulate conditions that would lead current practitioners to use ACEIs. Thus, we compared characteristics of VALIANT patients with those of patients in placebo-controlled trials that established ACEIs as standard treatment. Methods and Results: We collected demographic, clinical, medication and imaging information from 14703 patients in 24 countries. This high-risk population was a median 65.8 years old, and 31.1% were female. Most (51.8%) showed imaging evidence of LVSD at enrollment. Most (72%) had Killip class≥II HF. Patients received evidence-based therapies at rates similar to those of contemporary MI trials and at an improved rate compared with prior placebo-controlled ACEI trials. Conclusion: VALIANT represents the largest globally representative cohort enrolled with HF and/or LVSD after MI. Patients were similar to those in placebo-controlled ACEI trials while reflecting improvements in evidence-based care. With enrollment complete, VALIANT is poised to define the optimal strategy for renin–angiotensin system blockade after MI to improve cardiovascular outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1388-9842(03)00112-0

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 95

Metadata

Authors
Velazquez, E. J., Pfeffer, M. A., McMurray, J. V., Maggioni, A. P., Rouleau, J.-L., Van de Werf, F., Kober, L., White, H. D., Swedberg, K., Leimberger, J. D., Gallo, P., Sellers, M. A., Edwards, S., Henis, M., Califf, R. M., & for the VALIANT Investigators
Venue
European Journal of Heart Failure
Published
2003-08-01
Volume
5
Issue
4
Pages
537-544
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W2149523545
Cited by
95
References
3
FWCI
3.35
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: VALsartan In Acute Myocardial Infarction (VALIANT) Trial: Baseline Characteristics in Context. https://app.cochat.ai/papers/10.1016/s1388-9842(03)00112-0
The paper
Velazquez, E. J., Pfeffer, M. A., McMurray, J. V., Maggioni, A. P., Rouleau, J.-L., Van de Werf, F., Kober, L., White, H. D., Swedberg, K., Leimberger, J. D., Gallo, P., Sellers, M. A., Edwards, S., Henis, M., Califf, R. M., & for the VALIANT Investigators. (2003). VALsartan In Acute Myocardial Infarction (VALIANT) Trial: Baseline Characteristics in Context. European Journal of Heart Failure. https://doi.org/10.1016/s1388-9842(03)00112-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.